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Anticoagulation in Dilated Cardiomyopathy
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Philadelphia, Pennsylvania and Boston, Massachusetts
Patients with dilated cardiomyopathy have multiple factors
that predispose to thromboembolic events. However, reports of the
incidence of thromboembolic events in this population vary
widely. There has never been a controlled study of long-term
anticoagulation among patients with congestive heart failure due
to dilated cardiomyopathy. In this report we review the available
published data regarding the risk of thromboembolic events in
patients with dilated cardiomyopathy, and the effectiveness and
risks of anticoagulation in this population. Although many inves-
tigators have called for a prospective, randomized clinical trial to
assess the risks and benefits of long-term anticoagulation in
patients with dilated cardiomyopathy, a more practical approach
may be to compile a national registry of patients with dilated
cardiomyopathy to collect observational data on both the rate of
embolic events as well as bleeding complications among patients
with and without anticoagulation.
(J Am Coll Cardiol 1998;31:745–8)
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There has never been a controlled study of long-term antico-
agulation among patients with congestive heart failure (CHF)
due to dilated cardiomyopathy. Reports of the incidence of
thromboembolic events in this population vary widely. In this
article, we summarize key studies, assess the risks and propose
guidelines for anticoagulation among patients with dilated
cardiomyopathy.
Incidence of Thromboembolism in CHF:
Smaller Studies
Factors that predispose to thromboembolic events in pa-
tients with CHF include low cardiac output, with relative stasis
of blood in dilated cardiac chambers, poor contractility and
regional wall motion abnormalities and concomitant atrial
fibrillation. Early autopsy studies reported a very high fre-
quency of thromboembolic events. In 1958, Spodick and
Littman (1) reviewed reported autopsy cases of patients with
CHF and found that 50% had evidence of thromboembolism
(TE) at autopsy. Roberts et al. (2) in 1987 reviewed 152
consecutive patients with dilated cardiomyopathy and ob-
served a 37% frequency of thromboembolic events.
More recently, investigators have reported a lower inci-
dence of thromboembolic events. Fuster et al. (3), in a
retrospective study of 104 patients with nonischemic dilated
cardiomyopathy, reported an 18% frequency of thromboem-
bolic events and an incidence of 3.5 clinically apparent events/
100 patient-years. In 1993, Katz et al. (4) prospectively fol-
lowed 264 patients with dilated cardiomyopathy and reported
that the incidence of stroke was 1.7/100 patient-years. Finally,
in 1995, Natterson et al. (5) retrospectively studied 224 pa-
tients awaiting heart transplantation (mean left ventricular
ejection fraction [LVEF] 0.20) and found that only 6 (3%, or
3.2/100-patient years) had an episode of arterial embolization
over a mean follow-up period of 301 days.
Incidence of Thromboembolism in CHF:
Large Therapeutic Trials
Several clinical trials involving patients with CHF reported
on the incidence of TE in their study populations, but none
evaluated anticoagulation or thromboembolic events as a
primary end point. In the Vasodilators in Heart Failure
(V-HeFT) trials (6,7), the overall rate of TE was between 2.2
and 2.5/100 patient-years (8). Patients with a lower LVEF and
peak exercise oxygen consumption (MVO2) had a higher risk
of stroke, but only the difference in MVO2 was statistically
significant.
Although anticoagulation reduces the risk of stroke after
acute (and especially anterior) myocardial infarction (9,10),
this is not necessarily the case in chronic CHF, even when
caused by ischemic cardiomyopathy. Based on data from
V-HeFT, there appears to be no statistically significant differ-
ence in the rate of TE between patients with ischemic and
nonischemic dilated cardiomyopathy.
In the Survival and Ventricular Enlargement (SAVE) trial
(11), the incidence of stroke was 1.5/100 patient-years (12).
Risk was increased in patients who were older (63 6 9 vs. 59 6
11 years, p , 0.001). In SAVE, like V-HeFT, patients with a
lower LVEF had a higher rate of stroke. Patients with an
LVEF #28% had a nearly twofold increase in relative risk of
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stroke compared with patients with an LVEF .28% (relative
risk [RR] 1.86, p 5 0.01). For every 5% decrease in LVEF,
there was an 18% increase in stroke rate. When balanced
terciles based on LVEF were constructed, the total cumulative
stroke rate was significantly higher in the tercile of LVEF 9%
to 28% versus the tercile of LVEF .35%.
The most recent analysis (13) of the incidence of thrombo-
embolic events in patients with cardiomyopathy comes from a
retrospective review of Studies of Left Ventricular Dysfunction
(SOLVD) data (14,15). This analysis, in contrast to the studies
previously discussed, included only patients known to be in
normal sinus rhythm at the time of randomization. Although
the overall incidence of thromboembolic events was similar to
that for other large clinical trials, an unexpected finding was
that women were at increased risk for thromboembolic events
compared with men (2.4 events/100 patient-years vs. 1.8 events/
100 patient-years). Moreover, although a decrease in LVEF
was not associated with an increased risk of TE in men, each
10% decline in LVEF was significantly associated with a 53%
increased risk of TE among women. Women within the lowest
two quartiles of LVEF had an incidence of TE almost twice
that of men (Table 1). This finding may be due to gender
differences in the clotting or fibrinolytic system, the effects of
hormonal variations or simply chance.
Effectiveness of Anticoagulation
There has never been a controlled study of anticoagulation
among patients with CHF. Accordingly, the effectiveness of
anticoagulation must be judged by assessing observational data
in patients with CHF who were treated with anticoagulant
agents for a variety of reasons, such as atrial fibrillation, a
previous thromboembolic event, or known left ventricular
thrombus, or empirically. Additionally, most studies do not
correct for the presence of a well established risk for TE such
as atrial fibrillation. Finally, neither the decision to initiate
anticoagulant therapy nor the level of anticoagulation was
specified or controlled as part of any study protocol.
In the study by Fuster et al. (3), there were 19 embolic
events over 624 patient years in the 103 patients who were not
treated with anticoagulant agents (3.5 events/100 patient-
years), whereas none of the 32 patients who received warfarin
(101 patient-years) had an embolic complication (p , 0.05).
Natterson et al. (5) documented arterial embolization in 5
(4%) of 142 patients not receiving warfarin and in 1 (1%) of 82
patients receiving anticoagulation (p 5 0.30). Of the nine
patients who had a cerebral TE in the study by Katz et al. (4),
5 were receiving long-term anticoagulation; notably, however,
3 of these patients had left ventricular thrombus documented by
two-dimensional echocardiography, and 1 had atrial fibrillation.
In contrast, the V-HeFT studies (6–8) failed to show any
protective effect of anticoagulation; in fact, patients treated
with anticoagulant agents had the same or higher rates of
thromboembolic events. In V-HeFT I, the thromboembolic
event rate in patients treated with anticoagulant agents (2.9/
100 patient-years) was similar to that in patients not receiving
anticoagulation (2.7/100 patient-years, p 5 NS). Ironically,
V-HeFT II demonstrated that patients receiving anticoagula-
tion had a higher thromboembolic event rate (4.9/100 patient-
years) than those not receiving anticoagulation (2.1/100
patient-years), a difference that achieved statistical significance
(p 5 0.01). Because neither the decision to initiate anticoag-
ulation nor the intensity of anticoagulation was controlled, it is
likely that patients judged to be at highest risk for TE (e.g., those
with atrial fibrillation or known LV thrombus or even patients
with mechanical valve replacement) were treated with warfarin.
Although the SAVE trial (12) had an 81% risk reduction in
stroke among patients receiving anticoagulant agents, antico-
agulant therapy was not randomized, and its intensity was not
controlled. In addition, aspirin use alone reduced the relative
risk for stroke in the SAVE trial by 56%. Finally, the recent
analysis of the SOLVD database (13) failed to show a reduc-
tion in thromboembolic events among either men (RR 0.97,
95% confidence interval [CI] 0.65 to 1.44, p 5 0.87) or women
(RR 1.34, 95% CI 0.56 to 2.71, p 5 0.60) receiving anticoag-
ulation.
Risks of Anticoagulation
Although the rate of TE increases with CHF, especially in
the elderly and in those with reduced LVEFs, controlled
Abbreviations and Acronyms
CHF 5 congestive heart failure
CI 5 confidence interval
LVEF 5 left ventricular ejection fraction
MVO2 5 peak exercise oxygen consumption
RR 5 relative risk
SAVE 5 Survival and Ventricular Enlargement
SOLVD 5 Studies of Left Ventricular Dysfunction
SPAF 5 Stroke Prevention in Atrial Fibrillation
TE 5 thromboembolism
V-HeFT 5 Vasodilators in Heart Failure
Table 1. Incidence and Crude Relative Risk of Thromboembolic
Events According to Gender and Left Ventricular Ejection
Fraction Quartiles in Studies of Left Ventricular Dysfunction
(SOLVD) Trial*
LVEF Incidence RR (95% CI)
Men (n 5 5,457)
$30% 1.70 1.00
21%–30% 1.83 1.08 (0.83–1.41)
11%–20% 2.01 1.21 (0.86–1.70)
#10% 1.96 1.21 (0.30–4.92)
Women (n 5 921)
$30% 1.78 1.00
21%–30% 2.41 1.35 (0.74–2.47)
11%–20% 3.80 2.17 (1.10–4.30)
#10% 4.20 2.43 (0.32–18.26)
*Adapted, with permission, from Dries et al. (13). CI 5 confidence interval;
LVEF 5 left ventricular ejection fraction; RR 5 relative risk.
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clinical trials have not addressed the effectiveness or the risks
of long-term anticoagulation in this patient population. Several
studies (16–20) have found the incidence of major hemorrhage
in patients receiving anticoagulation to range from 2.3 to
6.8/100 patient-years (Table 2). Intracranial bleeding is the
most feared hemorrhagic event. van der Meer et al. (17)
calculated a rate of intracranial bleeding of 0.62/100 patient-
years, whereas the Stroke Prevention in Atrial Fibrillation
(SPAF) II investigators (20) calculated an even higher rate of
0.9/100 patient-years.
Unfortunately, older age increases the likelihood of major
bleeding as well as the rate of TE among patients with CHF. In
the van der Meer study (17), compared with patients ,40 years
old, each 10-year increase in age was associated with 46% more
major bleeding. Fihn et al. (19) similarly found that even after
adjustments were made for the intensity of anticoagulation,
patients $80 years old had a fourfold greater risk of life-
threatening or fatal bleeding. Finally, SPAF II (20) also found
a significant increase in both the rates of intracranial bleeding
and major bleeding in patients .75 years old.
Antiplatelet agents can cause bleeding complications, but
this occurs far less frequently than with anticoagulant agents.
Although low dose aspirin carries a risk of gastrointestinal
hemorrhage, review of the various placebo-controlled aspirin
trials suggests that the risk is especially increased when higher
doses (.1,000 mg) are used (21).
Benefits of Aspirin Monotherapy
The efficacy of aspirin as an antithrombotic agent is well
established. Among previously healthy male physicians, it
reduced the incidence of myocardial infarction and death (22).
Among patients with unstable angina, 75 mg of aspirin taken
daily halves the rate of myocardial infarction and death (23).
Aspirin also reduces the incidence of stroke and death in
patients with a history of transient ischemic attacks (24) and
reduces the rate of stroke and systemic embolism in patients
with atrial fibrillation (25). Although there has never been a
randomized trial of aspirin for TE risk reduction in patients
with dilated cardiomyopathy, the clinical trials of patients with
CHF suggest that aspirin monotherapy may be beneficial in
this regard.
In V-HeFT I (8), the incidence of TE in patients receiving
aspirin monotherapy was 0.5 events/100 patient-years com-
pared with 2.7 events/100 patient-years in patients receiving no
antiplatelet or anticoagulant agents (p 5 0.07). Similarly,
V-HeFT II (8) demonstrated that the incidence of TE in
patients receiving aspirin was 1.6 events/100 patient-years
compared with 2.1 events/100 patient-years in patients receiv-
ing no treatment, although this difference was not significant
(p 5 0.48).
In the SAVE trial (12), aspirin use significantly reduced the
risk of stroke by 56%. The protective effect of aspirin was most
pronounced in patients with an LVEF #28%; in this group,
aspirin use was associated with a reduction in risk of stroke of
66% (p , 0.001). Similarly, the SOLVD trial (13) showed a
beneficial effect of aspirin monotherapy, especially in women.
The use of antiplatelet agents was associated with a 23%
reduction in the risk of TE in men (p 5 0.06); in women,
antiplatelet monotherapy was associated with a marked 53%
reduction in risk (p 5 0.03). In the SOLVD trial (26), aspirin
monotherapy was also associated with a 24% reduction in the
risk of sudden death.
Recommendations
Although certain groups of patients with CHF have well
defined indications for chronic anticoagulation (previous
thromboembolic event, atrial fibrillation and the presence of
newly formed left ventricular thrombus [27,28]), evidence from
published reports does not demonstrate convincingly that the
benefits of anticoagulation exceed the risks in other subgroups.
Moreover, the fluctuating metabolic state of patients with
dilated cardiomyopathy may predispose to bleeding complica-
tions. Patients with dilated cardiomyopathy often have a
chronically low cardiac output that may impair hepatic and
renal function. Furthermore, they often require multiple med-
ications that may interact with warfarin.
Because of the potential for increased bleeding complica-
tions in patients with dilated cardiomyopathy, anticoagulant
therapy, when indicated, should be administered under the
most controlled circumstances. We recommend that, whenever
possible, patients be monitored in properly managed antico-
agulation clinics that can minimize bleeding complications
(29,30).
The only clear-cut indications for anticoagulation in most
patients with dilated cardiomyopathy are atrial fibrillation, a
previous thromboembolic event or left ventricular thrombus.
Recent analyses of the SAVE (12) and SOLVD (13) databases
have shown that low dose aspirin may be quite useful in
preventing TE and may be much less risky than warfarin. In
patients with underlying coronary artery disease, aspirin prob-
ably confers additional benefit.
Although some investigators have called for a prospective,
randomized clinical trial of long-term anticoagulation in pa-
tients with dilated cardiomyopathy (31,32), such a trial may not
be feasible. The low rate of TE would necessitate an unrealis-
tically large study size. One would also have to contend with
resistance by physicians and their patients to the concept of
randomization, primarily due to the strongly held beliefs of
individual clinicians regarding anticoagulant therapy. Instead,
a more practical initial approach might be to compile registries
Table 2. Risks of Anticoagulation: Rates of Major Hemorrhage
Study (ref no.) No. of Patients
Event Rate
(per 100 patient-years)
SPAF II (16) 1,100 2.3
van der Meer et al. (17) 6,814 2.7
Gitter et al. (18) 61 5.3
Fihn et al. (19) 376 6.8
ref 5 reference; SPAF 5 Stroke Prevention in Atrial Fibrillation trial.
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of patients with dilated cardiomyopathy, in which observa-
tional data on embolic events as well as bleeding complications
are collected for patients with and without anticoagulation.
Such registries might be initiated not only within individual
institutions but also among consortia of community hospitals,
outpatient offices and health maintenance organizations to
gain realistic insights into the outcomes encountered in various
settings. While such data are being collected and analyzed, the
most prudent approach will be risk stratification of patients
with dilated cardiomyopathy to help determine which patients
will have the largest net clinical benefit from long-term anti-
coagulation.
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